Cargando…
Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585]
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288649/ http://dx.doi.org/10.1186/2051-1426-2-S3-P45 |
| _version_ | 1782352002781544448 |
|---|---|
| author | Bhardwaj, Nina Merad, Miriam Kim-Schulze, Seunghee Crowley, Beth Davis, Thomas Keler, Tibor Salazar, Andres Brody, Joshua |
| author_facet | Bhardwaj, Nina Merad, Miriam Kim-Schulze, Seunghee Crowley, Beth Davis, Thomas Keler, Tibor Salazar, Andres Brody, Joshua |
| author_sort | Bhardwaj, Nina |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288649 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42886492015-01-15 Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585] Bhardwaj, Nina Merad, Miriam Kim-Schulze, Seunghee Crowley, Beth Davis, Thomas Keler, Tibor Salazar, Andres Brody, Joshua J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288649/ http://dx.doi.org/10.1186/2051-1426-2-S3-P45 Text en Copyright © 2014 Bhardwaj et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Bhardwaj, Nina Merad, Miriam Kim-Schulze, Seunghee Crowley, Beth Davis, Thomas Keler, Tibor Salazar, Andres Brody, Joshua Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585] |
| title | Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585] |
| title_full | Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585] |
| title_fullStr | Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585] |
| title_full_unstemmed | Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585] |
| title_short | Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585] |
| title_sort | converting tumors into vaccine manufacturing factories: dc recruitment, activation and clinical responses with a flt3l-primed in situ vaccine for low-grade lymphoma [nct01976585] |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288649/ http://dx.doi.org/10.1186/2051-1426-2-S3-P45 |
| work_keys_str_mv | AT bhardwajnina convertingtumorsintovaccinemanufacturingfactoriesdcrecruitmentactivationandclinicalresponseswithaflt3lprimedinsituvaccineforlowgradelymphomanct01976585 AT meradmiriam convertingtumorsintovaccinemanufacturingfactoriesdcrecruitmentactivationandclinicalresponseswithaflt3lprimedinsituvaccineforlowgradelymphomanct01976585 AT kimschulzeseunghee convertingtumorsintovaccinemanufacturingfactoriesdcrecruitmentactivationandclinicalresponseswithaflt3lprimedinsituvaccineforlowgradelymphomanct01976585 AT crowleybeth convertingtumorsintovaccinemanufacturingfactoriesdcrecruitmentactivationandclinicalresponseswithaflt3lprimedinsituvaccineforlowgradelymphomanct01976585 AT davisthomas convertingtumorsintovaccinemanufacturingfactoriesdcrecruitmentactivationandclinicalresponseswithaflt3lprimedinsituvaccineforlowgradelymphomanct01976585 AT kelertibor convertingtumorsintovaccinemanufacturingfactoriesdcrecruitmentactivationandclinicalresponseswithaflt3lprimedinsituvaccineforlowgradelymphomanct01976585 AT salazarandres convertingtumorsintovaccinemanufacturingfactoriesdcrecruitmentactivationandclinicalresponseswithaflt3lprimedinsituvaccineforlowgradelymphomanct01976585 AT brodyjoshua convertingtumorsintovaccinemanufacturingfactoriesdcrecruitmentactivationandclinicalresponseswithaflt3lprimedinsituvaccineforlowgradelymphomanct01976585 |